A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer

Pediatric Blood and Cancer

Volumn 61, Issue 4, 2014, Pages 636-642

  Robison, Nathan J ^a,b   Campigotto, Federico ^a   Chi, Susan N ^a,b   Manley, Peter E ^a,b   Turner, Christopher D ^a,b   Zimmerman, Mary Ann ^a,b   Chordas, Christine A ^a,b   Werger, Annette M ^a,b   Allen, Jeffrey C ^c   Goldman, Stewart ^d   Rubin, Joshua B ^e   Isakoff, Michael S ^f   Pan, Wilbur J ^g   Khatib, Ziad A ^h   Comito, Melanie A ⁱ   Bendel, Anne E ^j,k   Pietrantonio, Jay B ^a,b   Kondrat, Laura ^a,b   Hubbs, Shannon M ^a,b   Neuberg, Donna S ^a   Kieran, Mark W ^a,b   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e ST LOUIS CHILDREN S HOSPITAL   (United States)

^f Farmington   (United States)

^g ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^h FLORIDA INTERNATIONAL UNIVERSITY   (United States)

ⁱ PENN STATE CHILDREN S HOSPITAL   (United States)

^j CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

Angiogenesis; Drug resistance; Pediatric oncology; Phase II clinical trials

Indexed keywords

CARBOPLATIN; CELECOXIB; CYCLOPHOSPHAMIDE; ETOPOSIDE; FENOFIBRATE; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE; THALIDOMIDE; THROMBOSPONDIN; VINBLASTINE;

ARTICLE; BLOOD TOXICITY; BONE TUMOR; CANCER RECURRENCE; DRUG WITHDRAWAL; EPENDYMOMA; FEMALE; GLIOMA; HUMAN; INFECTION; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; METRONOMIC DRUG ADMINISTRATION; MULTICENTER STUDY; NEOPLASM; NEPHROBLASTOMA; NEUROBLASTOMA; NEUROECTODERM TUMOR; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS; DRUG RESISTANCE; PEDIATRIC ONCOLOGY; PHASE II CLINICAL TRIALS;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; FENOFIBRATE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROSPECTIVE STUDIES; PYRAZOLES; SULFONAMIDES; SURVIVAL RATE; THALIDOMIDE; YOUNG ADULT;

EID: 84893462355     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24794     Document Type: Article

References (31)

1. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012; 30:679-692.
2. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285:1182-1186.
3. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res 1986; 46:467-473.
4. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 2004; 3:430-446.
5. Doolittle ND, Anderson CP, Bleyer WA, et al. Importance of dose intensity in neuro-oncology clinical trials: Summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. Neuro Oncol 2001; 3:46-54.
6. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-1886.
7. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105:R15-R24.
8. Panigrahy D, Kaipainen A, Butterfield CE, et al. Inhibition of tumor angiogenesis by oral etoposide. Exp Ther Med 2010; 1:739-746.
9. Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: Clinical implications and future strategies. J Clin Oncol 2012; 30:4026-4034.
10. Manley PW, Martiny-Baron G, Schlaeppi J-M, et al. Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs 2002; 11:1715-1736.
11. Kerbel RS. Reappraising antiangiogenic therapy for breast cancer. Breast 2011; 20:S56-S60.
12. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005; 27:573-581.
13. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: New rationale for new directions. Nat Rev Clin Oncol 2010; 7:455-465.
14. Stempak D, Gammon J, Halton J, et al. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 2006; 28:720-728.
15. André N, Rome A, Coze C, et al. Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: A preliminary monocentric study. Clin Ther 2008; 30:1336-1340.
16. Fousseyni T, Diawara M, Pasquier E, et al. Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01. J Pediatr Hematol Oncol 2011; 33:31-34.
17. Talpur R, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002; 47:672-684.
18. Stienstra R, Duval C, Müller M, et al. PPARs, obesity, and inflammation. PPAR Res 2007; 2007:95974.
19. Goetze S, Eilers F, Bungenstock A, et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 2002; 293:1431-11437.
20. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104:365-372.
21. Panigrahy D, Kaipainen A, Huang S, et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct, indirect angiogenesis inhibition. Proc Natl Acad Sci USA 2008; 105:985-990.
22. Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 2012; 30:1358-1363.
23. Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: A report from the Children's Oncology Group. J Clin Oncol 2012; 30:2641-2647.
24. Gustafson SA, Lin P, Chen SS, et al. Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. Am J Clin Pathol 2009; 131:647-655.
25. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009; 52:791-795.
26. Chamberlain MC. Recurrent intracranial ependymoma in children: Salvage therapy with oral etoposide. Pediatr Neurol 2001; 24:117-121.
27. Peyrl A, Chocholous M, Kieran MW, et al. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer 2012; 59:511-517.
28. Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001; 7:427-436.
29. Jiménez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6:41-48.
30. Bocci G, Francia G, Man S, et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003; 100:12917-12922.
31. Zapletalova D, André N, Deak L, et al. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: A multicenter experience. Oncology 2012; 82:249-260.